Richmond Pharmacology is excited to join the CRISPR Medicine Conference 2026 in Copenhagen, Denmark, on 14–16 April 2026.

This global conference brings together pioneers in gene editing, therapeutic development, and genome engineering to explore cutting‑edge CRISPR technologies and their translation into safe, effective clinical applications.

Representing Richmond Pharmacology:

  • Stephen Wilkinson, Business Development Manager
  • Tom Ashdown, Associate Medical Director

Our Focus at the Conference

  • Advances in CRISPR‑based therapeutics and delivery systems
  • Clinical translation of gene‑editing technologies
  • Regulatory and ethical considerations for genome‑editing trials
  • Safety assessment strategies for first‑in‑human and early‑phase CRISPR studies
  • Collaboration across industry, academia, and regulatory communities

Connect With Us

If you are attending the CRISPR Medicine Conference 2026 and would like to explore collaboration or development opportunities:

📧 fasteranswers@richmondpharmacology.com

Find out more here: The 3rd CRISPR Medicine Conference Copenhagen, April 14-16th, 2026, CRISPRMED26

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event